Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.83% |
| 2 | Healthcare | 3.13% |
| 3 | Technology | 2.97% |
| 4 | Financials | 2.19% |
| 5 | Consumer Discretionary | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SGI
14351
Somnigroup International
SGI
$14.3B
| $57 | ﹤0.01% |
1
-13,073
| -100% | -$698K |
2024 Q3
1 quarter
|
|
|
ELEV
14352
CALL
DELISTED
Elevation Oncology
ELEV
| $56 | ﹤0.01% |
100
-600
| -86% | -$354 |
2024 Q1
3 quarters
|
|
14353
XBiotech
XBIT
$66.8M
| $51 | ﹤0.01% |
+13
| New | +$89 |
2024 Q4
0 quarters
|
|
|
EDVA
14354
PUT
Endovia Health Sciences, Inc.
EDVA
$1.1M
| $48 | ﹤0.01% |
2
+1
| +100% | +$33 |
2022 Q3
9 quarters
|
|
|
KLRS
14355
PUT
Kalaris Therapeutics
KLRS
$64.3M
| $42 | ﹤0.01% |
4
-5
| -56% | -$76 |
2022 Q3
9 quarters
|
|
|
OMGA
14356
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $37 | ﹤0.01% |
49
| – | – |
2024 Q1
3 quarters
|
|
|
GOEV
14357
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $35 | ﹤0.01% |
25
-2,464
| -99% | -$26.8K |
2023 Q2
6 quarters
|
|
14358
Forward Air
FWRD
$537M
| $32 | ﹤0.01% |
1
-300
| -100% | -$10.5K |
2024 Q3
1 quarter
|
|
14359
Seres Therapeutics
MCRB
$29.5M
| $26 | ﹤0.01% |
+2
| New | +$33 |
2024 Q4
0 quarters
|
|
|
KNDI
14360
Kandi Technologies Group
KNDI
$82.4M
| $25 | ﹤0.01% |
21
+18
| +600% | +$23 |
2021 Q1
15 quarters
|
|
|
FNUC
14361
Frontier Nuclear and Minerals Inc
FNUC
$46M
| $19 | ﹤0.01% |
+2
| New | +$9 |
2024 Q4
0 quarters
|
|
14362
Gran Tierra Energy
GTE
$369M
| $14 | ﹤0.01% |
2
| – | – |
2021 Q1
15 quarters
|
|
|
AZUL
14363
DELISTED
Azul
AZUL
| $13 | ﹤0.01% |
8
-3,062
| -100% | -$7.98K |
2017 Q2
30 quarters
|
|
14364
Citius Pharmaceuticals
CTXR
$14.6M
| $4 | ﹤0.01% |
+1
| New | +$7 |
2024 Q4
0 quarters
|
|
14365
Direxion Daily AAPL Bull 2X ETF
AAPU
$170M
| – | – |
-50,489
| Closed | -$1.89M | – |
|
14366
CALL
Abits Group
ABTS
$3.79M
| – | – |
-133
| Closed | -$1.02K | – |
|
|
14367
Abits Group
ABTS
$3.79M
| – | – |
-997
| Closed | -$7.66K | – |
|
14368
ALPS Clean Energy ETF
ACES
$99.5M
| – | – |
-7,843
| Closed | -$231K | – |
|
14369
PUT
AC Immune
ACIU
$271M
| – | – |
-100
| Closed | -$378 | – |
|
14370
Aptus Behavioral Momentum ETF
ADME
$310M
| – | – |
-6,592
| Closed | -$305K | – |
|
14371
Addus HomeCare
ADUS
$2.08B
| – | – |
-34,329
| Closed | -$4.34M | – |
|
14372
CALL
Advantage Solutions
ADV
$354M
| – | – |
-144
| Closed | -$12.3K | – |
|
|
14373
Advantage Solutions
ADV
$354M
| – | – |
-619
| Closed | -$53.1K | – |
|
|
14374
PUT
Advantage Solutions
ADV
$354M
| – | – |
-12
| Closed | -$1.03K | – |
|
14375
Antelope Enterprise Holdings
AEHL
$190M
| – | – |
-5
| Closed | -$15.2K | – |
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors's Q4 2024 filing shows 1,745 new, 6,427 increased, 6,082 reduced and 1,421 closed positions. Its largest new stake was Zoetis: 1,090,499 shares worth $178M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,421 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.